Ghrelin is a multifaceted gut hormone that activates its receptor, growth hormone secretagogue receptor (GHS-R). Ghrelin's hallmark functions are its stimulatory effects on growth hormone release, food intake and fat deposition. Ghrelin is famously known as the 'hunger hormone'. However, ample recent literature indicates that the functions of ghrelin go well beyond its role as an orexigenic signal. Here, we have reviewed some of the most recent findings on ghrelin and its signalling in animals and humans.
INTRODUCTION
Ghrelin is a 28-aa Ser3 acylated peptide, and its functionally relevant endogenous receptor is growth hormone secretagogue receptor (GHS-R). Ghrelin is a key regulator of nutrient sensing, meal initiation and appetite [1, 2] . Apart from its orexigenic effect, research in the last decade has shown that ghrelin has regulatory roles in many organs and systems [1] [2] [3] . Ghrelin signalling has increasingly been recognized as a key regulator of obesity, insulin resistance and diabetes; intriguingly, many of these regulatory functions appear to be independent of ghrelin's effect on food intake [ 
GLUCOSE HOMEOSTASIS
Glucose homeostasis is a highly complex process, controlled by neuroendocrine hormones that regulate glucose uptake, storage and disposal processes. Ghrelin has been shown to play an important role in glucose homeostasis. The majority of studies report that ghrelin inhibits insulin secretion, although some studies also observe stimulation or no effect on insulin secretion [21] . The differential effects of ghrelin on insulin secretion appear to be correlated with ghrelin and/or glycemic conditions [21] . A recent study [22 && ] suggests that ghrelin's effect on insulin secretion depends on the heteromerization between GHS-R and the somatostatin receptor 5, both of which are G-protein coupled receptors (GPCRs). The heteromerization varies according to the ratio of somatostatin:ghrelin in the serum; this ratio determines whether the Ga(i/o) subunit or the Ga(q) subunit is being activated, which leads to activation of different signal transduction pathways that result in different insulin responses to ghrelin [22 && ]. Studies using leptin-deficient obese and diabetic ob/ob mice and ghrelin -/-.ob/ob mice demonstrated that the ablation of ghrelin improves the diabetic phenotype with increased insulin secretion, reduced blood glucose and improved glucose tolerance [6] . Mitochondrial uncoupling protein 2 (UCP2), decreasing ATP production to lower the ATP:ADP ratio, is a key regulator for insulin secretion [23] . The pancreases of ghrelin -/-.ob/ob mice show lower UCP2 expression than that of ob/ob mice, suggesting that ghrelin negatively affects insulin secretion by regulating UCP2 in the pancreatic cells [6] . Surprisingly, studies involving ghrelin receptor knockout mice (Ghsr -/-) suggest that GHS-R has an opposite effect on glucose regulation compared with ghrelin [9 & ]. The hyperglycemic phenotype of Ghsr -/-:ob/ob mice is actually worse than that of ob/ob mice. The Ghsr -/-:ob/ob mice have lower insulin, higher blood glucose and worsened glucose tolerance [9 & ]. Histological analysis of islets reveals that Ghsr -/-:ob/ob mice have islets similar in size than ob/ob mice, which implies that the cell mass of the islets is not affected in the mice; this points towards an effect of cell function. Unlike ghrelin -/-:ob/ob mice, UCP2 expression is significantly higher in pancreases of Ghsr -/-:ob/ob mice, explaining the reduced insulin secretion [9 & ]. Given the findings that ghrelin ablation and GHS-R ablation have paradoxical effects on glycemic control, ghrelin's inhibitory effect on insulin secretion may be mediated by a yet unknown receptor(s) other than GHS-R. These results highlight the complexity of the ghrelin signalling pathway in pancreatic cells; thus, it is critically important to distinguish the effects of ghrelin antagonism from that of GHS-R antagonism for the regulation of glucose homeostasis.
Ghrelin has also been shown to be essential in maintaining glucose homeostasis during starvation. Ghrelin acylation is activated by ghrelin O-acyltransferase (GOAT). GOAT -/mice exhibit extreme hypoglycemia under 60% calorie restriction [24] . The hypoglycemic phenotype of GOAT -/mice can be rescued by infusion of ghrelin, growth hormone (GH), lactate or fatty acid [10 & ]. This suggests that ghrelin increases glucose production by activating gluconeogenic processes and/or GH-regulated pathways. However, a recent study [25] of GOAT -/-, ghrelin -/-, Ghsr -/and ghrelin -/and Ghsr -/doubleknockout mice under 50% calorie restriction failed to observe this extreme hypoglycemia.
The counter-regulatory response to hypoglycemia is an important component of glucose homeostasis. This response is mediated by glucagon from the pancreatic islets [26, 27] , catecholamines from adrenal glands [28] and GH from the anterior pituitary [29] , which synergistically increase hepatic glucose output. There is evidence of feedback regulation between ghrelin and glucagon. A study [30] in mouse islets and a-cells demonstrates that ghrelin, via GHS-R, directly stimulates glucagon secretion in pancreatic cells. Ghrelin's effect on glucagon secretion is regulated by intracellular calcium flux and phosphorylation of extracellular signal regulated kinase (ERK) [30] . Conversely, glucagon, along with norepinephrine, has been shown to stimulate ghrelin secretion via the mitogen-activated protein kinase (MAPK) and exchange protein activated by cAMP (EPAC) pathways in nutrientdeficient conditions [31 & ]. Glucose production by the liver is an important therapeutic target for the treatment of type 2 diabetes (T2D). Metformin, a drug commonly used to treat T2DM, reduces hepatic gluconeogenesis [32] . In primary gastric cells, it is demonstrated that metformin treatment inhibits ghrelin production through activation of AMP-activated protein kinase (AMPK) [33 & ]. This portends an interesting connection between the antidiabetic effects of metformin and ghrelin's inhibitory effect on insulin secretion. Studies using ghrelin -/and Ghsr -/mice recently reveal increased gluconeogenesis and glycogenolysis in hepatic tissues during the postabsorptive state, suggesting that the ghrelin-GHS-R axis may inhibit the production of glucose and the breakdown of glycogen in the liver [11 & ]. It is worth noting that this study was done in a postabsorptive state; it may not reflect glucose regulation under fasting conditions when glucagon is activated. The central nervous system (CNS) also has an important role in the regulation of glucose
KEY POINTS
Ghrelin ablation improves glucose homeostasis, whereas GHS-R ablation worsens it.
GHS-R ablation increases energy expenditure, attenuating age-associated obesity and insulin resistance.
Ghrelin reduces sympathetic nerve activity and has a cardioprotective effect.
Ghrelin prevents muscle atrophy.
Ghrelin regulates bone formation/bone metabolism.
homeostasis. In a recent study [34 & ], a Phox2b-Cre driven system was utilized to induce GHS-R expression exclusively in the hindbrain region of global GHS-R knockout mice. Global GHS-R knockout mice exhibit hypoglycemia under fasting conditions, but re-expression of GHS-R in the hindbrain only rescues the hypoglycemic phenotype but not ghrelin-induced food intake [34 & ]. Notably, systemic ghrelin injections increase the cFos expression in the hindbrain of wild-type mice, but not in the Phox2b-Cre driven GHSR re-expression mice; this suggests that GHS-R action in hindbrain is independent of ghrelin [34 & ]. In another study [35] , ghrelin stimulates the dopaminergic neurons in the ventral tegmental area (VTA), but re-expression of GHS-R in these neurons cannot rescue fasting hypoglycemia, although it partially increases food intake. These data suggest that the glycemic and orexigenic effects of ghrelin signalling are regulated at different neurons in the brain.
ENERGY HOMEOSTASIS
Energy homeostasis depends on the balance between energy intake and energy expenditure. Dysregulation of energy homeostasis results in obesity or anorexia. It is well documented that ghrelin is orexigenic, increasing calorie intake [1] [2] [3] 36, 37] . Central and peripheral administration of ghrelin increases adipogenesis and lipogenesis, but decreases lipolysis. Interestingly, the adipogenic effects appear to be independent from ghrelin's orexigenic function [4, 5] .
Apart from energy intake, ghrelin also affects energy expenditure. It was recently reported that administration of ghrelin antibody to mice increases fasting energy expenditure [12 && ]. This study suggests that ghrelin can regulate energy balance in addition to energy intake. Adult Ghsr -/mice show reduced body weight [38] ; the phenotype becomes more pronounced in older (9 months or older) mice. Older Ghsr À/À mice are lean and insulin-sensitive, but exhibit no difference in food intake or physical activity [7] . Consistently, the older Ghsr -/mice show a healthier lipid profile with decreased cholesterol and triglycerides, and improved insulin sensitivity. The metabolic profile analyses indicate that the lean and insulin-sensitive phenotype of older Ghsr -/mice is due to increased energy expenditure [7] . Recent studies have shown that nonshivering thermogenesis in brown fat plays a crucial role in energy balance in adult humans; thermogenic impairment during ageing leads to decreased energy expenditure and obesity [39] [40] [41] . Older Ghsr -/mice have a higher core body temperature due to increased thermogenesis in brown fat [7] . Further cellular and molecular characterization reveals that there is higher mitochondrial content and elevated expression of uncoupling protein 1 (UCP1) in the brown fat [7] . In the presence of fatty acids, UCP1 (also called thermogenin) uncouples oxidative phosphorylation from ATP synthase by facilitating proton movement across the mitochondrial inner membrane, resulting in heat generation [39] . The thermogenic phenotype of Ghsr -/mice indicates that GHS-R is an important regulator of thermogenesis. GHS-R ablation increases energy expenditure independent of food intake or physical activity, suggesting that GHS-R antagonists may represent a novel approach to combat obesity.
CARDIAC FUNCTIONS
Ghrelin is present in human cardiomyocytes. Myocardial infarction (MI) often is accompanied by malignant ventricular arrhythmia and increased cardiac sympathetic nerve activity (CSNA) [42] . Ghrelin has been shown to act on the vagal nerves to prevent the increase of CSNA and arrhythmia, improving the survival prognosis of MI [13 && ]. Furthermore, during the recovery phase after MI, ghrelin prevents excessive sympathetic activation by reducing epinephrine and norepinephrine, thus improving the function of the heart [14] .
In rodent models, ghrelin administration induces changes that promote angiogenesis. A recent study [15 & ] in a rat model of cardiopulmonary bypass shows that ghrelin treatment reduces inflammatory responses, apoptosis and oxidative stress induced by CPB, and preserves the cardiac pumping function through GHS-R1a and Akt signalling. Increased angiogenesis is measured by changes in vascular endothelial growth factor (VEGF), VEGF receptor and nitric oxide [43] . Ghrelin treatment in rat model of MI demonstrates increased VEGF expression and angiogenesis [16] . In diet-induced obese mice, systemic ghrelin treatment increases serum VEGF and decreases nitric oxide concentrations [43] . Overall, ghrelin treatment may reduce CSNA inflammation and oxidative stress in the heart, and induce angiogenesis. More studies are needed to further assess whether ghrelin is beneficial for treating heart diseases.
MUSCLE ATROPHY
Muscle atrophy, characterized by reduced muscle mass and impaired muscle function, accompanies many diseases, including cachexia from cancer or AIDS, and muscle denervation. Ghrelin can indirectly increase muscle mass by increasing food intake and activating the GH/insulin-like growth factor-1 (IGF-1) axis in cachexia mice [17] . It has been shown that ghrelin promotes myocyte differentiation and fusion in C2C12 myoblasts [44] . A recent study [18 && ] further demonstrates that the protective effect of ghrelin in fasting and denervation-induced muscle atrophy is mediated by mammalian target of rapamycin (mTOR) and Akt signalling. Intriguingly, this study shows that both acylated and unacylated ghrelin have protective effects on muscle atrophy [18 && ]. Of note, these antiatrophic effects do not appear to be associated with the activation of the GH/IGF-1 axis. Also, as unacylated ghrelin does not bind to GHS-R, the muscular functions of ghrelin and unacylated ghrelin are likely to be mediated by a yetunidentified receptor [18 && ].
BONE METABOLISM
Ghrelin and GHS-R1a are expressed in rat osteoblasts; ghrelin increases proliferation and differentiation of osteoblasts in vitro and bone mineral density (BMD) in vivo [45] . It has been shown that ghrelin regulates bone formation and mass by activating phosphorylation of AMPK [46] . Ghrelin treatment has no effect on differentiation of rat osteoclasts, but promotes proliferation of human osteoblasts, although these cells only express the inactive receptor isoform GHS-R1b [47] . The result suggests that ghrelin's effect on bone turnover may not be mediated by GHS-R1a. It is recently reported that ghrelin, interacting with leptin, regulates osteoclastogenesis and bone metabolism in an age-dependent manner [ ] shows that chronic central administration of ghrelin increases bone mass independent of food intake or weight gain. A study [48] in healthy elderly women shows positive correlation between serum ghrelin and trabecular BMD, using quantitative computed tomography (CT). Thus, ghrelin promotes bone formation and increases bone mass; however, but its effect on bone metabolism may be age-dependent.
THERAPEUTIC POTENTIALS
Ghrelin mimetics and antibodies, as well as GHS-R agonists and antagonists, may be utilized therapeutically for various conditions. The therapeutic potential of ghrelin's orexigenic property has been intensively explored. Ghrelin increases appetite [1, 2] ; patients with anorexia nervosa or cachexia have been shown to benefit from ghrelin therapy [49, 50] . A clinical trial using oral ghrelin (anamorelin) for treatment of cancer-induced cachexia is now in Phase III [51] . A recent study [52] also suggests that ghrelin in saliva can be used as a marker for early onset of eating disorders.
With increasing knowledge of nonorexigenic properties of ghrelin and GHS-R, now ghrelin signalling is also thought to hold promising therapeutic potential for plethora of other conditions. Ghrelin improves cardiac functions and survival prognosis after MI and CPB by reducing sympathetic nerve activity [ ]. Ghrelin improves skeletal muscle catabolism by activating GH/IGF-1 axis and prevents muscle atrophy by promoting muscle differentiation and fusion [17,18 && ], suggesting that ghrelin might be used to treat muscle wasting diseases such as muscle dystrophy and sarcopenia. Similar to ghrelin, unacylated ghrelin also exhibits antiatrophic effect on muscle [18 && ]. However, as unacylated ghrelin does not increase GH nor food intake/adiposity, it represents an exciting new option for the prevention/treatment of muscle waste, but avoids the cancer risk associated with ghrelin-induced GH release and obesity associated with ghrelin-induced food intake. As the identity of the receptor for unacylated ghrelin is yet unknown, the biological and therapeutic implications revealed here demand further investigation.
On the contrary, new findings suggest that antagonism of ghrelin or GHS-R is beneficial for obese and insulin-resistant conditions. Ghrelin treatment decreases insulin secretion and stimulates glucagon secretion in pancreatic islets [6, 30] , and ghrelin ablation rescues the hyperglycemic phenotype of leptin-deficient diabetic mice [6] ; thus, ghrelin blockers may function as antidiabetic agents. However, because antagonism of ghrelin and GHS-R appears to have opposite effects on glycemic regulation [6,9 & ], further studies are needed to fully understand the molecular mechanisms by which ghrelin and GHS-R regulate pancreatic beta-cell functions. Ghrelin can increase adiposity independent from food intake [4, 5] ; ghrelin neutralization and GHS-R ablation increase energy expenditure by enhancing thermogenesis, without affecting food intake or activity [7,12 && ]. Thus, ghrelin antibodies and/or GHS-R antagonists may represent an extremely promising new class of antiobesity therapy independent from diet or exercise.
CONCLUSION
In addition to its role as the 'hunger hormone', ghrelin has much broader functions (Fig. 1) . Ghrelin regulates glucose homeostasis through inhibition of insulin secretion and regulation of hepatic glucose output. Ghrelin signalling regulates energy homeostasis by decreasing thermogenesis to reduce energy expenditure. Ghrelin also has cardioprotective effect in the heart and antiatrophic effect in the muscle. Moreover, ghrelin also regulates bone formation/metabolism. All of these roles reveal the exciting therapeutic potential for targeting ghrelin and/or its receptor. However, as ghrelin and GHS-R have effects on many organs with both beneficial and detrimental effects, caution must be taken to avoid side-effects when developing therapies. This study in rats shows that chronic ICV administration of ghrelin increases bone mass and demonstrates that the effect is independent from ghrelin's orexigenic function.
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